Difference between revisions of "Aldesleukin (Proleukin)"
m |
m |
||
| Line 16: | Line 16: | ||
*[http://chemocare.com/chemotherapy/drug-info/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 5/5/1992: Initial FDA approval | ||
==References== | ==References== | ||
| Line 22: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
| + | |||
[[Category:Bone cancer medications]] | [[Category:Bone cancer medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1992]] | ||
Revision as of 21:05, 5 November 2014
Also known as interleukin-2, IL-2, or Macrolin.
General information
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Aldesleukin (Proleukin) patient drug information (Chemocare)[4]
- Aldesleukin (Proleukin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/5/1992: Initial FDA approval